Catch up on the top radiology content of the past week.

For patients with metastatic castration-resistant prostate cancer (mCRPC), researchers found that (177Lu)Lu-PSMA-I&T led to a PSA50 response in over 44 percent of patients with no reports of grade 3 or worse renal toxicity, according to a newly published multicenter study.

For patients with intermediate-risk prostate cancer, those with lower apparent diffusion coefficient (ADC) values on pre-treatment DWI MRI had a fourfold higher prevalence of distant metastasis in a study with a 10.3-year median follow-up.

In a recent episode of our Molecular Imaging in Focus series, Thomas Hope, MD, discussed challenges with conventional imaging for gliomas and the potential of the newly FDA-approved PET agent floretyrosine F18 (18F-FET) for differentiating between glioma progression and treatment-related effects.

New research demonstrates significantly higher specificity and inter-reader agreement with MRI-guided reconstruction in comparison to standard ordered-subset expectation-maximization (OSEM) reconstruction of PET imaging for amyloid assessment.

Catch up on the top radiology content of the past week.

Catch up on the latest imaging research from the recent European Society of Cardiology (ESC) Congress.

The PET radiotracer JBS-003 (18F-fluoromisonidazole) is currently being evaluated in a phase 3 randomized trial for facilitating de-escalation of radiation therapy in patients with HPV-positive oropharyngeal carcinoma.